自体外周血造血干细胞移植治疗恶性淋巴瘤的远期疗效

目的：观察自体外周血造血干细胞移植治疗恶性淋巴瘤的远期疗效。方法：我院行自体外周血造血干细胞移植治疗的恶性淋巴瘤患者共39例，其中非霍奇金淋巴瘤32例，霍奇金淋巴瘤7例，移植前状态：移植前患者达CR1 21例，CR。9例，PR9例。结果：移植后CR32例，PR7例，无移植相关死亡。全部病例随访至2014年2月，随访时间6～105个月，3年以上23例，5年以上16例。1例霍奇金恶性淋巴瘤Ⅳb期患者（病理分型为混合细胞型）移植后11个月出现复发，移植后13个月死亡。1例弥漫大B淋巴瘤移植后6个月死于肝功能衰竭，8例NHL患者分别于移植后21，25，26，27，31，32，63，83个月死于复发或进展。其余29例存活至今（CR22例，带瘤生存7例），3年无事件生存率（EFS）为78．3％（18／23）和；5年EFS为56．2％（9／16）；总生存率74．4％（29／39）。结论：自体外周血造血干细胞移植作为恶性淋巴瘤患者缓解后的巩固治疗比单纯化疗有更好的疗效，对提高无事件生存率和总生存率可能有益，值得进一步探讨。

Long-term effect of autologous peripheral blood stem cell transplantation on the treatment of malignant Iymphoma

Objective： To observe the long-term effect of autologous peripheral blood stem cell trans- plantation（APBSCT）on malignant lymphoma. Methods： 39 patients were treated with APBSCT in our hospital. Of which, 32 patients were with non-Hodgkin＇s Lymphoma（NHL） and 7 patients with Hodgkin Lymphoma（HL）. Before transplantation, there were 21 CR1cases, 9 CRzcases, and 9 partial response（PR） cases. Results： After transplantation, there were 32 CR cases, 7 PR cases, and there was no transplant-related death. All cases were followed up till Feb of 2014, and the time of follow-up ranged from 6 to 105 months. 23 cases hadbeen followed up more ore than 3 years and 16 cases more than 5 years. 1 patient with HL（Pathological type was nodular sclerosis） died of re lapse at 13 months after the transplantation, 1 patient with diffuse large B cell lymphoma died ofhepatic failure at 6 months after transplantation, and 8 patients with NHL died of relapse or progress of the disease at 21, 25, 26, 27, 31, 32, 63 and 83 months after transplantation respectively. The other 29 patients remained alive（including 22 CR cases, 7 cases survived with tumor）. The event free survival（EFS） rate of 3 years was 78. 3%（18/23）, and the EFS rate of 5 years was 56.2%（9/16）, and overall survival（OS） rate was 74.4% （29/39）. Conclusion： APBSCT, as the the consolidation therapy for malignant lymphoma patients after the remission therapy, has better effect than that treated by only chemotherapy, and it may be beneficial to improve the EFS and OS rate of patients.